Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations
Commercial team preparing for potential gene therapy launches
“We are thrilled to welcome Robin and Brad to the Orchard team, with their decades of experience and proven success leading international and domestic commercial operations for companies targeting rare diseases,” said
About Orchard
Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis, the first autologous ex vivo gene therapy approved by the
Orchard currently has offices in the
Forward-Looking Statements
This press release contains certain forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchard’s expectations regarding timing of regulatory submissions for approval of its product candidates, the likelihood of approval of such product candidates by the applicable regulatory authorities, and Orchard’s ability to commercialize such product candidates, if approved, in
Contacts
Corporate contact
+1 202-669-6786
katie.payne@orchard-tx.com
Media contact
LifeSci Public Relations
+1 516-655-0842
Allison@lifescipublicrelations.com
Source: Orchard Therapeutics